Norethindrone Acetate in the Medical Management of Adenomyosis
AbstractThe role of norethindrone acetate (NA) in the management of adenomyosis was evaluated with a retrospective chart review of 28 premenopausal women between 27–49 years of age presenting with moderate to severe pelvic pain and bleeding. Bleeding and dysmenorrhea scores were analyzed using paired T-tests. There was significant improvement of both dysmenorrhea and bleeding after treatment. Age showed no correlation with dysmenorrhea or bleeding. Low dose NA could be considered an effective, well-tolerated and inexpensive medical alternative to surgery for treating symptomatic adenomyosis. Large multicentric studies may help validate our findings.
Scifeed alert for new publicationsNever miss any articles matching your research from any publisher
- Get alerts for new papers matching your research
- Find out the new papers from selected authors
- Updated daily for 49'000+ journals and 6000+ publishers
- Define your Scifeed now
Muneyyirci-Delale, O.; Chandrareddy, A.; Mankame, S.; Osei-Tutu, N.; Gizycki, H. Norethindrone Acetate in the Medical Management of Adenomyosis. Pharmaceuticals 2012, 5, 1120-1127.
Muneyyirci-Delale O, Chandrareddy A, Mankame S, Osei-Tutu N, Gizycki H. Norethindrone Acetate in the Medical Management of Adenomyosis. Pharmaceuticals. 2012; 5(10):1120-1127.Chicago/Turabian Style
Muneyyirci-Delale, Ozgul; Chandrareddy, Ashadeep; Mankame, Siddhi; Osei-Tutu, Nanna; Gizycki, Hans von. 2012. "Norethindrone Acetate in the Medical Management of Adenomyosis." Pharmaceuticals 5, no. 10: 1120-1127.